The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism.

IF 1 4区医学 Q3 UROLOGY & NEPHROLOGY

Clinical nephrology Pub Date : 2025-08-20 DOI:10.5414/CN111695

Eiichi Sato, Miyako Urata, Shohei Sato, Takao Ono, Manaka Degawa, Hongmei Lu, Mayumi Nomura, Daisuke Matsumura, Noriaki Moriyama, Mayuko Amaha, Tsukasa Nakamura

{"title":"The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism.","authors":"Eiichi Sato, Miyako Urata, Shohei Sato, Takao Ono, Manaka Degawa, Hongmei Lu, Mayumi Nomura, Daisuke Matsumura, Noriaki Moriyama, Mayuko Amaha, Tsukasa Nakamura","doi":"10.5414/CN111695","DOIUrl":null,"url":null,"abstract":"Aims: No English-language research papers have reported on the clinical use of upacicalcet, a novel intravenous calcimimetic agent for the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. Therefore, this study aimed to investigate the outcomes of switching from etelcalcetide to upacicalcet.Materials and methods: The subjects included 37 hemodialysis patients with SHPT treated with etelcalcetide before switching to upacicalcet. This study was a single-center retrospective study conducted in Japan. Serum levels of corrected calcium (Ca), phosphorus (P), intact parathyroid hormone (iPTH), and the dose of maxacalcitol were assessed at 3 and 6 months after switching to upacicalcet.Results: As a result of the switch from etelcalcetide to upacicalcet, the serum corrected Ca level remained unchanged, from 8.9 ± 0.6 to 9.1 ± 0.7 mg/dL (p = 0.104) at 3 months and to 9.0 ± 0.6 mg/dL (p = 0.197) at 6 months. Meanwhile, the serum P level decreased from 6.3 ± 1.5 to 5.8 ± 1.5 mg/dL (p = 0.069) at 3 months and to 5.9 ± 1.9 mg/dL (p = 0.039) at 6 months. The iPTH level increased slightly, from 153.8 ± 100.3 pg/mL to 176.4 ± 124.6 pg/mL (p = 0.337) at 3 months and to 206.5 ± 168.7 pg/mL (p = 0.017) at 6 months. Multiple regression analysis revealed that the change in iPTH was related to the change in P levels.Conclusion: These findings suggested that upacicalcet may be a useful option for managing serum P levels in hemodialysis patients with SHPT.","PeriodicalId":10396,"journal":{"name":"Clinical nephrology","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5414/CN111695","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: No English-language research papers have reported on the clinical use of upacicalcet, a novel intravenous calcimimetic agent for the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. Therefore, this study aimed to investigate the outcomes of switching from etelcalcetide to upacicalcet.

Materials and methods: The subjects included 37 hemodialysis patients with SHPT treated with etelcalcetide before switching to upacicalcet. This study was a single-center retrospective study conducted in Japan. Serum levels of corrected calcium (Ca), phosphorus (P), intact parathyroid hormone (iPTH), and the dose of maxacalcitol were assessed at 3 and 6 months after switching to upacicalcet.

Results: As a result of the switch from etelcalcetide to upacicalcet, the serum corrected Ca level remained unchanged, from 8.9 ± 0.6 to 9.1 ± 0.7 mg/dL (p = 0.104) at 3 months and to 9.0 ± 0.6 mg/dL (p = 0.197) at 6 months. Meanwhile, the serum P level decreased from 6.3 ± 1.5 to 5.8 ± 1.5 mg/dL (p = 0.069) at 3 months and to 5.9 ± 1.9 mg/dL (p = 0.039) at 6 months. The iPTH level increased slightly, from 153.8 ± 100.3 pg/mL to 176.4 ± 124.6 pg/mL (p = 0.337) at 3 months and to 206.5 ± 168.7 pg/mL (p = 0.017) at 6 months. Multiple regression analysis revealed that the change in iPTH was related to the change in P levels.

Conclusion: These findings suggested that upacicalcet may be a useful option for managing serum P levels in hemodialysis patients with SHPT.

查看原文本刊更多论文

在继发性甲状旁腺功能亢进的血液透析患者中，替替卡肽转换为升帕卡肽的效果。

目的：目前还没有关于upacicalcet（一种新型静脉溶钙剂）用于治疗血液透析患者继发性甲状旁腺功能亢进（SHPT）的临床应用的英文研究论文报道。因此，本研究旨在探讨从替替卡肽转向替替卡肽的结果。材料与方法：研究对象为37例SHPT血液透析患者，患者在转入upacicalcet前曾使用依替卡肽治疗。本研究是在日本进行的单中心回顾性研究。在3个月和6个月后，分别评估校正后的血清钙（Ca）、磷(P)、完整甲状旁腺激素（iPTH）水平和美沙骨化醇的剂量。结果：从替替卡肽切换到upacicalcet后，血清校正钙水平保持不变，3个月时从8.9±0.6 mg/dL降至9.1±0.7 mg/dL (p = 0.104)， 6个月时降至9.0±0.6 mg/dL （p = 0.197）。3个月时血清P水平由6.3±1.5 mg/dL降至5.8±1.5 mg/dL (P = 0.069)， 6个月时降至5.9±1.9 mg/dL （P = 0.039）。iPTH水平略有升高，3个月时由153.8±100.3 pg/mL增至176.4±124.6 pg/mL (p = 0.337)， 6个月时增至206.5±168.7 pg/mL （p = 0.017）。多元回归分析显示iPTH的变化与P水平的变化有关。结论：这些发现表明，upacicalcet可能是控制SHPT血液透析患者血清P水平的有效选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical nephrology 医学-泌尿学与肾脏学

CiteScore

2.10

自引率

9.10%

发文量

138

审稿时长

4-8 weeks

期刊介绍： Clinical Nephrology appears monthly and publishes manuscripts containing original material with emphasis on the following topics: prophylaxis, pathophysiology, immunology, diagnosis, therapy, experimental approaches and dialysis and transplantation.